Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
SCTR Biologics Sequence Review Report 2026: Secretin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of SCTR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RAMP2 Biologics Sequence Review Report 2026: Receptor activity-modifying protein 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of RAMP2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RAMP3 Biologics Sequence Review Report 2026: Receptor activity-modifying protein 3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of RAMP3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RET Biologics Sequence Review Report 2026: Proto-oncogene tyrosine-protein kinase receptor Ret Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of RET protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTH2R Biologics Sequence Review Report 2026: Parathyroid hormone 2 receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTH2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
RAMP1 Biologics Sequence Review Report 2026: Receptor activity-modifying protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of RAMP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTGIR Biologics Sequence Review Report 2026: Prostacyclin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGIR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTGER3 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP3 subtype Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGER3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTGFR Biologics Sequence Review Report 2026: Prostaglandin F2-alpha receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTGER4 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP4 subtype Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGER4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PRLHR Biologics Sequence Review Report 2026: Prolactin-releasing peptide receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PRLHR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTGER1 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP1 subtype Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGER1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
207
208
209
210
211
>>
1872
>